Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 6Melanoma 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma 2Drug-Related Side Effects and Adverse Reactions 2Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Kidney Neoplasms 1Immunoblastic Lymphadenopathy 1Carcinoma, Renal Cell 1

Interventions

aldesleukin 15pembrolizumab 11Cyclophosphamide 9fludarabine phosphate 7fludarabine 6Nivolumab 6Interleukin-2 6atezolizumab 5Radiotherapy 5Ipilimumab 4Interferon-alpha 4Drug Therapy 4Blood Specimen Collection 4Radiosurgery 3tremelimumab 2temsirolimus 2durvalumab 2cemiplimab 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Paclitaxel 2Metformin 2Interleukin-12 Subunit p35 2Genistein 2Gene Expression Profiling 2Flow Cytometry 2Filgrastim 2Cetuximab 2zanolimumab 1vivitrol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × denileukin diftitox × Dermatologic × Clear all
NCT00082914 2013-06-20

Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡